Skip to main content
. 2017 Nov 28;1(25):2486–2490. doi: 10.1182/bloodadvances.2017005637

Table 1.

Impact of combination rituximab regimens on depth of response and PFS

ORR (%) VGPR/CR (%) PFS (mo)
Standard rituximab 40 0-5 13
Extended rituximab 60 5-10 16-29
Thalidomide rituximab 70 10 30%
Cyclophosphamide rituximab 70-80 20-25 30-36
Nucleoside analogs rituximab 70-90 20-30 36-62
Proteasome inhibitors rituximab 80-90 30-40 42-66
Bendamustine rituximab 90 30 69